abacavir/lamivudine / Generic mfg. - LARVOL DELTA

Pharmacokinetics of abacavir and lamivudine in infants living with HIV with and without rifampicin co-treatment. (PubMed, J Antimicrob Chemother) - P2/3 | "Rifampicin co-treatment had minimal impact on abacavir and lamivudine pharmacokinetics in infants. Dose adjustment of abacavir/lamivudine is not required during rifampicin-containing tuberculosis treatment."

Journal • PK/PD data • Human Immunodeficiency Virus • Infectious Disease • Pediatrics • Pulmonary Disease • Respiratory Diseases • Tuberculosis

Patterns of dolutegravir resistance in Malawi’s national HIV program 2021-2025 (AIDS 2026) - "In univariable LG analysis, the odds of intermediate/high-level dolutegravir resistance were higher with AZT/3TC and ABC/3TC backbones (vs. TDF/3TC), male sex and presence of NRTI resistance. While 95% of Malawians on dolutegravir-based regimens have suppressed VL, among those with confirmed virological failure, high-level dolutegravir resistance increased over time and was associated with dolutegravir exposure duration. Intermediate/high-level dolutegravir resistance was independently associated with NRTI resistance. These insights may inform future prioritization of HIVDR testing in an evolving global HIV funding landscape."

Human Immunodeficiency Virus • Infectious Disease

Comparative safety of B/F/TAF versus other antiretroviral therapy regimens for treatment-experienced people with HIV-1: a systematic literature review and network meta-analysis. (PubMed, J Comp Eff Res) - "Triglycerides changes favored B/F/TAF versus DTG/ABC/3TC (-15.01 [-29.18, -1.06]) and protease inhibitor (+ or /) b + 2 NRTIs (-24.48 [-41.60, -7.47]). Switching to or remaining on B/F/TAF in TE PWH was generally well tolerated and did not worsen lipid, renal or safety outcomes versus most other contemporary ART. Improvements in select lipid parameters and stable renal function, with low rates of adverse events and discontinuation, support B/F/TAF as a safe option for long-term management in TE PWH."

Journal • Retrospective data • Human Immunodeficiency Virus • Infectious Disease • CD4

Safety and Effectiveness Analysis of Dolutegravir and Dolutegravir/Abacavir/Lamivudine in Japanese People Living with HIV: 10 years of Post-Marketing Surveillance. (PubMed, Adv Ther) - "This 10-year post-marketing surveillance confirms the long-term safety and effectiveness of single-agent DTG and DTG/ABC/3TC in Japanese PLHIV. No new safety concerns emerged over the 10-year surveillance period, further supporting their established safety profiles and reinforcing their continued role as key therapeutic options in routine clinical practice."

Journal • P4 data • Human Immunodeficiency Virus • Infectious Disease • CD4

Gestational and lactational exposure to HIV tri-combination therapy induces sex- and dose-dependent changes in inflammatory cytokine profiles, intestinal permeability, and villi morphology in adult rat offspring. (PubMed, Front Immunol) - "Our previous work has demonstrated dose-dependent changes in the fecal and mucosa-associated microbiome of adult rat offspring perinatally exposed to TC-ART (tri-combination ART: dolutegravir, abacavir, and lamivudine). In females, while some intestinal permeability genes were downregulated, the upregulation of other permeability genes suggests a compensatory mechanism to maintain the intestinal barrier function, indicating an overall milder response to TC-ART. These findings suggest that perinatal exposure to TC-ART may have differential impacts on intestinal health, with females exhibiting a more adaptive response compared to males, highlighting the need for sex-specific considerations in evaluating long-term effects of ART."

Journal • Preclinical • Human Immunodeficiency Virus • Infectious Disease • CSF1 • IL12A • IL17A • IL5 • IL7

Baseline resistance mutations and virological response to dolutegravir in treatment-naïve patients: a multicentre NGS study. (PubMed, J Antimicrob Chemother) - "Our findings indicate that pre-existing IN and RT DRM, including low-abundance and secondary/polymorphic variants, did not compromise the virological efficacy of dolutegravir-based triple therapy in ART-naïve individuals, supporting the high resistance barrier of dolutegravir and the lack of need for baseline resistance testing."

Journal • Next-generation sequencing • Retrospective data • Human Immunodeficiency Virus • Infectious Disease

Alternative Administration of Antiretroviral Therapy in People with HIV Unable to Swallow: A Scoping Review. (PubMed, HIV AIDS (Auckl)) - "Key findings included: (1) Bictegravir/emtricitabine/tenofovir alafenamide was associated with viral suppression when dissolved and administered enterally; (2) Dolutegravir/abacavir/lamivudine crushed via nasogastric tube was associated with viral suppression within 10 months; (3) Dolutegravir requires separation from enteral feeds containing polyvalent cations to avoid chelation and reduced absorption. Alternative administration ART, namely INSTI-based regimens and NRTIs, may help maintain viral suppression in these settings, provided that drug-specific pharmacokinetic considerations and enteral feeding interactions are addressed. Further prospective studies with therapeutic drug monitoring are needed to establish standardized protocols."

Journal • Review • Gastrointestinal Disorder • Human Immunodeficiency Virus • Infectious Disease

Doubling dolutegravir dosage reduces the viral reservoir in ART-treated people with HIV. (PubMed, Elife) - P2 | "Twenty HIV-infected adults, who had received a triple ART consisting of 50 mg DTG/600 mg abacavir/300 mg lamivudine pre-intensification and had been suppressed on ART for at least 2 years, were enrolled in a phase 2 randomized clinical trial (https://clinicaltrials.gov/ identifier: NCT05351684). Our results strongly suggest that the pre-intensification ART regimen was not completely suppressive. If confirmed in larger clinical trials, these results could have an impact on the clinical management of PWH and HIV curative strategies."

Clinical • Journal • Human Immunodeficiency Virus • Infectious Disease • Inflammation • CD4 • CD8

Graft-versus-HIV-reservoir reactivity: Long term HIV remission after allogeneic stem cell transplantation from a donor with active CCR5 (ASH 2025) - "Three years after alloSCT (September 2017), the patientdiscontinued antiretroviral therapy (Raltegravir and Abacavir/Lamivudine). This is the first case of HIV cure via alloSCT from a donor with active CCR5 and provides compellingevidence that "graft-versus-reservoir" reactivity is the key driver of viral reservoir clearance.For alloSCT recipients living with HIV and their caregivers, these data demonstrate the possibility of HIVcure even when no HIV resistant (CCR5 Δ32/ Δ32) alloSCT donor can be identified. Outside the alloSCTfield, our data builds the underlying rationale for HIV cure strategies based on effective viral reservoirreductions."

Clinical • Acute Graft versus Host Disease • Graft versus Host Disease • Human Immunodeficiency Virus • Immunology • Infectious Disease • Transplantation • CCR5 • CD4 • CXCR4 • FLT3

Doubling dolutegravir dosage reduces the viral reservoir in ART-treated people with HIV. (PubMed, medRxiv) - "Twenty HIV-infected adults, who had received a triple ART consisting of 50mg DTG/600 mg abacavir/300 mg lamivudine pre-intensification and had been suppressed on ART for at least two years, were enrolled in a phase 2 randomized clinical trial. Our results strongly suggest that the pre-intensification ART regimen was not completely suppressive. If confirmed in larger clinical trials, these results could have an impact on the clinical management of PWH and HIV curative strategies."

Clinical • Journal • Human Immunodeficiency Virus • Infectious Disease • Inflammation • CD4 • CD8

Effectiveness and safety of dolutegravir/lamivudine/abacavir versus bictegravir/emtricitabine/tenofovir alafenamide as first-line regimens in real-world settings (MICTLAN study). (PubMed, Int J STD AIDS) - "BIC/FTC/TAF was more effective in patients with low baseline CD4 + counts, while DTG/3TC/ABC performed better with higher viral loads. DTG/3TC/ABC had more neuropsychiatric AEs and rare hypersensitivity reactions."

Clinical • Journal • Real-world evidence • CNS Disorders • Human Immunodeficiency Virus • Immunology • Infectious Disease • Insomnia • Psychiatry • Sleep Disorder • CD4

Advanced coronary artery disease in a low-risk HIV patient – a case for early statin intervention (EACS 2025) - "His antiretroviral regimen initially was Kivexa and Efavirenz, which was then switched to Atripla in 2020 and switched to Descovy and Efavirenz in 2022. This case reinforces the inadequacy of relying solely on traditional risk scores for cardiovascular risk assessment in People Living With HIV(PLWH). Chronic inflammation and endothelial dysfunction associated with HIV infection may drive atherosclerosis independently of classical risk factors. In alignment with the REPRIEVE study outcomes, the BHIVA now recommends initiating statins in PLWH based on Q-Risk, advocating for early, primary preventive cardiovascular management in this population."

Clinical • Metastases • Human Immunodeficiency Virus • Infectious Disease • CD4

Incidence of Metabolic Dysfunction-Associated Steatotic Liver Disease in ART-Naïve People Living with HIV Initiating DTG/ABC/3TC vs. BIC/FTC/TAF: A 96-Week Analysis from a Mexican Cohort (EACS 2025) - "Clinicians should weigh these metabolic risks when selecting ART regimens, particularly for PLHIV with risk factors for liver disease. Larger studies with extended follow-up are needed to validate these results and elucidate underlying mechanisms."

Human Immunodeficiency Virus • Infectious Disease

Breastfeeding on ART and a closer look at drug transfer to HIV-exposed uninfected infants. (PubMed, Sci Rep) - "Maternal ART regimens included abacavir/lamivudine (n = 2), tenofovir alafenamide/emtricitabine (n = 1) or tenofovirdisoproxil/emtricitabine (n = 5) in combinations with rilpivirine (n = 3) (RPV), dolutegravir (n = 2) (DTG), raltegravir (n = 1), darunavir/ritonavir (n = 1), or nevirapine (n = 1). Given this variability and the potential for drug accumulation in individual cases, maternal therapeutic drug monitoring should be considered to identify elevated levels early on. In such situations, infant monitoring tailored to the individual may also be warranted."

Journal • Retrospective data • Hematological Disorders • Human Immunodeficiency Virus • Infectious Disease • Neutropenia

No evidence of an effect of the M184I/V on the doravirine/lamivudine/tenofovir switch efficacy in people living with HIV. (PubMed, AIDS) - "Among PLWHIV with antiretroviral experience, there was no evidence that switching to doravirine + lamivudine plus tenofovir affected short-term treatment response in individuals harboring HIV M184I/V mutations."

Journal • Human Immunodeficiency Virus • Infectious Disease

Unmasking Tacrolimus Toxicity due to the Hacked Liver System. (PubMed, Ther Drug Monit) - "This case highlights the importance of reviewing potential drug interactions before prescribing or dispensing drugs."

Journal • Anorexia • Candidiasis • Diabetes • Human Immunodeficiency Virus • Infectious Disease • Musculoskeletal Pain • Pain • Transplantation

No changes in weight, body composition or metabolic parameters after the switch to dolutegravir and lamivudine compared to continued treatment with dolutegravir, abacavir and lamivudine for virologically suppressed HIV infection (The AVERTAS trial). (PubMed, BMC Infect Dis) - "Continuing or discontinuing abacavir for 48 weeks was associated with modest gains in weight that did not differ between groups. Similarly, fat distribution, or metabolic parameters were comparable between groups."

Clinical • Journal • Human Immunodeficiency Virus • Infectious Disease

Cost-effectiveness of Different Antiretroviral Treatment in Patients HIV Naive (clinicaltrials.gov) - P4 | N=0 | Withdrawn | Sponsor: Juan A. Arnaiz | N=150 ➔ 0 | Unknown status ➔ Withdrawn

Enrollment change • HEOR • Trial withdrawal • Human Immunodeficiency Virus • Infectious Disease • CD4

Unique molecular signatures in rebound viruses from antiretroviral drug and CRISPR-treated HIV-1-infected humanized mice. (PubMed, Commun Biol) - "The LA-ART treatment contains nanoformulated dolutegravir, lamivudine, abacavir, and rilpivirine combinations, and the HIV-1 excision treatment is CRISPR-Cas9 targeting the HIV-1-LTR-gag. These define viral rebound in the dual-treated hu-mice. The data underscores the limited role of CRISPR excision in generating these rebound HIV-1 mutants from dual-treated hu-mice."

Journal • Preclinical • Human Immunodeficiency Virus • Infectious Disease

Ensuring access to essential HIV medicines, strengthening workforce capacity, and driving innovation (IAS-HIV 2025) - "Priority was given to first-line ARVs (ABC/3TC), Nevirapine, Cotrimoxazole (CTX), and Hydrochlorothiazide (HCTZ) for aging HIV patients in rural areas.LESSONS LEARNED: 1. This ongoing project highlights the importance of leveraging innovation to optimize processes and adapt practices to the unique challenges of rural and hard-to-reach areas. Tailored tools and training ensure the consistent supply of essential commodities, strengthening the management of HIV and related ailments. As the initiative progresses from 2022 to 2028, continued monitoring will provide insights to sustain and scale these improvements in underserved communities."

Human Immunodeficiency Virus • Infectious Disease

Assessing the effect of co-administration of Rifapentine with Dolutegravir on viral load suppression among recipients of care on tuberculosis preventive therapy in Delta, Ekiti and Osun States (IAS-HIV 2025) - "Dolutegravir (DTG) forms part of the adult first line regimens in combination with Tenofovir/Lamivudine as TLD or Abacavir/Lamivudine as ALD. Co-administration of 3-HP with Dolutegravir-based regimens did not have negative impact on viral load suppression rates in the absence of Dolutegravir dosage adjustment."

Human Immunodeficiency Virus • Infectious Disease • Respiratory Diseases • Tuberculosis

Comprehensive Cardiovascular Risk Profiling in People Living with HIV: Insights from the Japanese Adverse Drug Event Report Database. (PubMed, AIDS Res Hum Retroviruses) - "ART regimen classes (e.g., integrase strand transfer inhibitors, non-nucleoside reverse transcriptase inhibitors, and protease inhibitors) and backbone therapies [e.g., abacavir (ABC)/lamivudine] were included in the analysis. Our findings underscore a potentially heightened cardiovascular risk associated with ABC, particularly in older PLWH or those with diabetes. These results highlight the need to consider individual CVD risk profiles when selecting ART regimens and reinforce the importance of ongoing pharmacovigilance to guide safer, more personalized treatment strategies worldwide."

Adverse events • Journal • Cardiovascular • Diabetes • Dyslipidemia • Human Immunodeficiency Virus • Hypertension • Infectious Disease • Metabolic Disorders

Drug resistance mutations and phylogenetic analysis of HIV-1 subtypes B and F from mothers and children with vertical transmission. (PubMed, BMC Infect Dis) - "Differences in mutation profiles and antiretroviral resistance for NRTI and NNRTI drug classes were observed in half of the mother-child pairs, emphasising the importance of individualised therapeutic strategies."

Journal • Human Immunodeficiency Virus • Infectious Disease

Incidence of Metabolic syndrome in people with HIV without experienCe to antiretroviral Therapy who start doLutegravir based-regimen compared with bictegrAvir based-regimeN after 48 weeks (MICTLAN trial). (PubMed, AIDS) - "Incidence of MetS among PWH receiving an INSTI-based regimen was high, with no difference between BIC/TAF/FTC and DTG/ABC/3TC groups. Age, overweight and elevated visceral fat at baseline were all associated with MetS."

Journal • Human Immunodeficiency Virus • Infectious Disease • Metabolic Disorders • Obesity

Dolutegravir/Abacavir/Lamivudine in Acute HIV-1 Results in Rapid Suppression and Restoration of CD4 T-cell Subsets Without Accelerated Decay of Latent HIV-1. (PubMed, Open Forum Infect Dis) - "Thirty-four participants required rapid HLA-B*57 testing at screening; 97% resulted ≤24 hours, and 71% started ART ≤24 hours. Integrase-based ART during acute HIV-1 resulted in brisk viral suppression, preservation of CD4+ T-cell subsets, and decline in resting CD4+ T-cell infection."

Clinical • Journal • Hepatitis B • Human Immunodeficiency Virus • Infectious Disease • Inflammation • CD4 • CD8 • HLA-B